Alumis Inc. (ALMS)
Alumis Inc. (ALMS) Stock Price, Analysis & Data
| Bid | 24.28 |
| Market Cap | 3.22B |
| Revenue (ttm) | 7.4M |
| Net Income (ttm) | -438.96M |
| Beta | -0.67 |
| EPS (ttm) | -4.01 |
| PE Ratio (ttm) | n/a |
| Forward PE | -8.68 |
| P/B (ttm) | 7.07 |
| P/S (ttm) | 435.30 |
| Earnings Date | Nov 12, 2026 |
| Ask | 31.47 |
| Volume | 647,342 |
| Avg. Volume (20D) | 1,300,017 |
| Open | 25.26 |
| Previous Close | 25.50 |
| Day's Range | 24.36 - 25.32 |
| 52-Week Range | 3.76 - 31.35 |
| Analyst | Strong Buy |
| Price Target | 39 (56.75%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ALMS
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases....
Financial Performance
In 2025, Alumis's revenue was 24.05M, an increase of undefined% compared to the previous year's 0. Earnings were -243.32M, a decrease of -17.3%.
Financial StatementsAnalyst Forecast
According to 9 analyst ratings, the average rating for ALMS stock is "Strong Buy". The 12-month stock price forecast is 39, which is upside of 56.75% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
